90 results
424B3
BXRXQ
Baudax Bio, Inc.
22 Nov 23
Prospectus supplement
4:58pm
)
Operating expenses:
Research and development
General and administrative
Change in fair value of warrants and derivatives
Change in contingent consideration … , bank or other loans, through strategic research and development, licensing (including out-licensing) and/or marketing arrangements or through public
PRER14A
BXRXQ
Baudax Bio, Inc.
25 Aug 23
Preliminary revised proxy
4:01pm
currently store our T cells and research specimens at our research and development facilities and at the facilities of our clinical … research and development pipeline, other potential business development opportunities reviewed by the Board and the opportunities and risks presented
424B5
BXRXQ
Baudax Bio, Inc.
18 Aug 23
Prospectus supplement for primary offering
4:40pm
of ANJESO, research and development costs, manufacturing costs, the acquisition or licensing of other businesses, products or product candidates, working
8-K
EX-99.1
217lbo28i
16 Aug 23
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
8:11am
DEFA14A
EX-99.2
s0ofz twom66pfg8lq
9 Aug 23
Additional proxy soliciting materials
5:28pm
8-K/A
EX-99.2
84kaiwpz
9 Aug 23
Other Events
5:27pm
8-K
EX-99.1
x7nne34ac9 h0s
28 Jun 23
Other Events
4:31pm
8-K
EX-99.1
ihxmumgj8 hc4qa
12 May 23
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
8:16am
424B3
bw1word tn9
28 Apr 23
Prospectus supplement
4:02pm
424B3
nydyvhku1 ist6um6
5 Dec 22
Prospectus supplement
4:37pm